

Fig. 1



Fig. 2


12
10
8
6
4
2
0
0
2
4
6
8
10
TIMP-1 predicted (µg/L)
TIMP-1 calculated (µg/L)

Fig. 3



Fig. 4


150
120
90
60
30
0
TIMP-1 level (µg/L)
0
20
40
60
80
100
Percentile (%)

Fig. 5a


120
90
60
30
0
TIMP-1, EDTA plasma (µg/L)
0
30
60
90
120
TIMP-1, Citrate plasma (µg/L)

Fig. 5b



Fig. 6



Fig. 7

ELISA OF HUMAN MMP-9:TIMP-1 IN PLASMA



Fig. 8

ELISA OF FREE (NON-COMPLEXED) HUMAN TIMP-1 IN PLASMA



Fig. 9

Antibody tests:
Polyclonal antiMMP9 as catching
MAC19 as detection



Fig. 10

Antibody tests:
Polyclonal antiMMP9 as catching
MAC15 as detection



Fig. 11

Poly/MAC 19 assay - recovery in Citrate and EDTA plasma



Intra-assay variation: 9,6% for 24 triplicate measurements of control plasma pool

Fig. 12


ROC for colorectal cancer
Sensitivity
1 – Specficity
0.0
0.2
0.4
0.6
0.8
1.0
COLON (0.89)
RECTUM (0.84)
TOTAL (0.87)

Fig. 13


ROC for colorectal cancer/Dukes A+B
Sensitivity
1.0
0.8
0.6
0.4
0.2
0.0
0.0
0.2
0.4
0.6
0.8
1.0
1-Specficity
COLON (0.87)
RIGHT-COLON (0.91)
TOTAL (0.84)

Fig. 14


ROC for colorectal cancer
Sensitivity
1.0
0.8
0.6
0.4
0.2
0.0
0.0
0.2
0.4
0.6
0.8
1.0
1 – Specificity
AUC = 0.88

Fig. 15

TIMP-1 levels (µg/L, log scale) in EDTA plasma from different patient groups compared to healthy donor samples.



Fig. 16


ROC for colon cancer/right side
Sensitivity
1 – Specficity
0.0
0.2
0.4
0.6
0.8
1.0
CEA (0.80)
TIMP – 1 (0.93)
CEA + TIMP – 1 (0.95)

Fig. 17


ROC for colorectal cancer
Sensitivity
1.0
0.8
0.6
0.4
0.2
0.0
0.0
0.2
0.4
0.6
0.8
1.0
1 – Specficity
TOTAL TIMP – 1 (0.88)
FREE TIMP – 1 (0.61)
COMBINED (0.94)

Fig. 18


ROC for primary breast cancer
Sensitivity
1 – Specficity
0.0
0.2
0.4
0.6
0.8
1.0
AUC = 0.50

Fig. 19

TIMP-1 in citrate plasma from healthy females (n=87) and advanced breast cancer patients (n=19)



	Median TIMP-1	Mean +-sd
Breast cancer patients	236 µg/L	292 +- 331 µg/L
Healthy blood donors	62.0 µg/L	63.5 +-10.5 µg/L

Fig. 20